Use: Labeled indications
- 1.
Full indications and usage US FDA label
1. INDICATIONS AND USAGE Ketodan ® Foam, 2% is indicated for the topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. Ketodan ® Foam, 2% is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older (1). Limitations of Use Safety and efficacy of Ketodan ® Foam, 2% for treatment of fungal infections have not been established. Limitations of Use Safety and efficacy of Ketodan ® Foam, 2% for treatment of fungal infections have not been established.
Contraindications
4. CONTRAINDICATIONS None. None.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2. DOSAGE AND ADMINISTRATION Ketodan ® Foam, 2% should be applied to the affected area(s) twice daily for four weeks. Hold the container upright, and dispense Ketodan ® Foam, 2% into the cap of the can or other cool surface in an amount sufficient to cover the affected area(s). Dispensing directly onto hands is not recommended, as the foam will begin to melt immediately upon contact with warm skin.
Pick up small amounts of Ketodan ® Foam, 2% with the fingertips, and gently massage into the affected area(s) until the foam disappears. For hair-bearing areas, part the hair, so that Ketodan ® Foam, 2% may be applied directly to the skin (rather than on the hair). Avoid contact with the eyes and other mucous membranes. Ketodan ® Foam, 2% is not for ophthalmic, oral or intravaginal use.
Ketodan ® Foam, 2% should be applied to the affected area(s) twice daily for four weeks (2). Ketodan ® Foam, 2% is not for ophthalmic, oral, or intravaginal use (2).
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of ketoconazole foam, 2% in pediatric patients less than 12 years of age have not been established. Of the 672 subjects treated with ketoconazole foam, 2% in the clinical trials, 44 (7%) were from 12 to 17 years of age. [See Clinical Studies (14)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 672 subjects treated with ketoconazole foam, 2% in the clinical trials, 107 (16%) were 65 years and over. Clinical trials of ketoconazole foam, 2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.
Dosage forms
Philippines
- Cream: 20 mg/g
- Topical cream: 20 mg/g
- Shampoo: 20 mg/g, 20 mg/mL
- ) cream: 20 mg/g
Registered products in the Philippines
65 products registered with the Food and Drug Administration (FDA) Philippines list Ketoconazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products65
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ConagenKetoconazole | 20mg/g (2%) Topical CreamAluminum tube with HDPE Screw Cap x 5g, 10g, and 15g (Box of 1's) | OTC | Azarias Pharmaceutical Laboratories Inc.,Philippines | Trader: Eba Generisch Trading Inc. | DRP-14745 | Dec 21, 2028 | |
DerkazoleKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g | OTC | Lincoln Pharmaceuticals Ltd.India | Despina Pharma Inc. | DRP-12567 | Sep 2, 2027 | |
DermazoleKetoconazole | 20 mg / mL (2% w/v) ShampooAluminum Foil Sachet X 8 mL (Box of 20's) | HR | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DRHR-1992 | May 26, 2030 | |
DermazoleKetoconazole | 20 mg/mL (2% w/v) ShampooHDPE Bottle X 60 HDPE Bottle x 60 mL (50 mL net content) and 120 mL (100 mL net content)mL (50 mL Net Content) (Box of 1's) | HR | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRHR-1632 | Feb 9, 2031 | |
DermsurKetoconazole | 20 mg/mL (2% w/v) ShampooPET Bottle with Cap x 60 mL and 100 mL (Box of 1's) | HR | Nanz Med Science Pharma Pvt. Ltd.India | Pharma-Surrey International Inc. | HRP-695 | May 22, 2030 | |
EnnazoleKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Bellus Life Solutions, IncImporter: Aglobal Care, Inc. | DRP-11793-01 | Apr 29, 2027 | |
FungazoneKetoconazole | 20 mg/g (2% w/w) CreamLaminated Tube with White Cap x 15 g (Box of 1's) | OTC | Uniza Lifecare Pvt. Ltd.India | Lealmeds Pharmaceutical Inc.\Trader: M/S Pharmacare | DRP-15195 | Jun 7, 2029 | |
FungelleKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15g (Box of 1's) | OTC | S Kant Healthcare Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-14803-03 | Jan 11, 2029 | |
Funginil-KKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821 | Jun 29, 2027 | |
FungiselKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15 g (Box of 1's) | OTC | S Kant Healthcare Ltd.India | New Seammed IncImporter: Medinova Pharmaceutical Inc. | DRP-14803-02 | Jan 11, 2029 | |
Go-KetoKetoconazole | 20 mg/g (2% w/w) Topical CreamAluminum Tube x 15g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Orange Biotec Inc. | DRP-11476-01 | Mar 30, 2027 | |
GonazolKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15 g (Box of 1's) | OTC | S Kant Healthcare Ltd.India | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-14803-01 | Jan 11, 2029 | |
Healthcare Antifungal CreamKetoconazole | 2% (20 mg/g) CreamAluminum Tube x 10 g (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY38892 (For Export Only) | Dec 23, 2030 | |
ItcheketKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821-04 | Jun 29, 2027 | |
K-ZolKetoconazole | 20 mg/g (2% w/w Cream10 g and 15 g Aluminum Collapsible Tube with Cap (Box of 1's) | OTC | Yash Medicare Private LimitedIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DR-XY46666 | Jul 31, 2029 | |
KeedermKetoconazole | 20 mg/g (2% w/w) Cream20 Grams | OTC | West-Coast Pharmaceuticals Works Pvt. Ltd.India | Allegens Healthcare Philippines Inc. | DRP-18977 | Oct 12, 2031 | |
Kenz CreamKetoconazole | 20mg/g (2% w/w/) CreamLaminated Tube x 10g & 15g (Box of 1's) | OTC | KLM Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-13661 | Mar 29, 2028 | |
KermazoneKetoconazole | 20 mg/g (2% w/w) CreamLaminated Aluminum Tube x 10 g (Box of 1's) | OTC | Scott-Edil Pharmacia LimitedIndia | Despina Pharma Inc. | DRP-17363 | Nov 25, 2030 | |
KetakinKetoconazole | 20 mg/g (2%) Topical CreamAluminum Collapsible Tube x 10 g (Box of 1's); Aluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Nanjing Baijingyu Pharmaceutical Co., Ltd.China | Global Pharmatrade | DR-XY42537 | Sep 6, 2028 | |
KetazfloxKetoconazole | 20 mg/g (2% w/w) Topical Cream.Laminated Tube x 30g (Box of 1's) | OTC | Daiwik Pharmasphere Pvt. Ltd.India | FSPC Pharmaceuticals Inc. | DRP-14868 | Jan 25, 2029 | |
KeteenKetoconazole | 20 mg/g (2 % w/v) ShampooHDPE Bottle x 75 mL (Box of 1's) | Rx | Curetech SkincareIndia | Ambica International Corporation | HRP-422 | Apr 16, 2030 | |
KetmaKetoconazole | 20mg/g (2% w/w) Topical CreamAluminum Tube x 10g (Box of 1's) | OTC | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines OPC | DRP-14869 | Jan 25, 2029 | |
KetoconasaphKetoconazole | 20 mg/g (2% w/w) ShampooFoil Sachet x 6 mL (Box of 48's) | OTC | Azine Healthcare Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-12397 | Aug 1, 2027 | |
KetoconazanKetoconazole | 20 mg/g (2%) Topical CreamAluminum tube with HDPE Screw Cap x 5g, 10g, and 15g (Box of 1's) | OTC | Azarias Pharmaceutical Laboratories IncPhilippines | Triple 888 Medical And Pharma Inc. | DRP-14698-01 | Nov 29, 2028 | |
KetocorexKetoconazole | 20mg/g (2% w/w) Topical CreamAluminum Collapsible Tube x 10g, 15g, and 20g (Box of l’s) | OTC | Next Wave (India)India | Aarex Pharma Distributor | DRP-12387 | Jul 29, 2027 | |
KetofredKetoconazole | 20mg/g (2% w/w) Topical CreamLaminated Tube x 15g (Box of 1's) | OTC | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-14870 | Jan 25, 2029 | |
KetohabKetoconazole | 20mg/g (2% w/w) Topical CreamAluminum Tube x 10g (Box of 1’s) | OTC | Dae Hwa Pharmaceutical Co., Ltd.Korea | H & B Pharma International Inc. | DRP-12386 | Jul 29, 2027 | |
KetoprimeKetoconazole | 20 mg/g (2% w/w) Topical CreamAluminium Tube x 3.5g, 5g, 10g, 15g, 20g, and 30g (Box of 1's) | OTC | Primecare Lifesciences Laboratories Corp.Philippines | Trader: Life and Health Source Pharmaceutical Distribution Co. | DRP-15439 | Aug 1, 2029 | |
KetosorbKetoconazole | 20 mg/g (2% w/w) CreamLaminated Tube x 10 g (Box of 1's) | OTC | Rhydburg Pharmaceuticals Ltd.India | Pharmastar Int'l Trading Corp.Trader: Sheer Essentials | DRP-16875 | Aug 6, 2030 | |
KetovenasolKetoconazole | 20 mg/g (2% w/w) Topical CreamHDPE Collapsible Tube x 15 g (Box of 1's) | OTC | Gracure Pharmaceuticals Ltd.,India | AGlobal Care Inc.Importer: Aglobal Care, Inc. | DRP-15848 | Sep 23, 2029 | |
KetovidKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 5 g and 15 g | Rx | Hovid Bhd.Malaysia | Hovid, Inc. | DR-XY32502 | Nov 6, 2031 | |
KetovidKetoconazole | 20 mg/g (2% w/w) ShampooHDPE Bottle x 120 mL Box of 1's | HR | Hovid BerhadMalaysia | HOVID INC | DRHR-1801 | Sep 29, 2027 | |
KetoxolKetoconazole | 20mg/g (2%) Topical CreamAluminum tube with HDPE Screw Cap x 5g, 10g, and 15g (Box of 1's) | OTC | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-14698 | Nov 29, 2028 | |
KetozolKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 5 g and 15 g (Box of 1's) | Rx | Bal Pharma LimitedIndia | Endure Medical Inc.Importer: Singapore Genebio Inc. | DR-XY43328 | Apr 1, 2029 | |
KetsokantKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Aglobal Care, Inc. | DRP-11793 | Apr 29, 2027 | |
KezoKetoconazole | 2% w/v Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-4513 | Jul 18, 2028 | |
KezoleKetoconazole | 20mg/g (2% w/w) Topical CreamLaminated Tube x 5 g (Box of 1's) Laminated Tube x 10 g (Box of 1's) Laminated Tube x 15 g (Box of 1's) | Rx | Zee Laboratories LimitedIndia | Eon Pharmatek Inc. | DR-XY48644 | Mar 9, 2028 | |
KrenazolKetoconazole | 20 mg/g (2% W/W) CreamLaminated Tube X 30g (Box of 1's) | OTC | Kremoint Pharma Pvt. Ltd.India | Aglobal Care, Inc. | DRP-12189 | Jun 28, 2032 | |
KzoleKetoconazole | 20mg/g (2% w/w) Topical CreamAluminum Tube x 15g (Box of 1's) | OTC | S. Kant Healthcare LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-11476 | Mar 30, 2027 | |
LatosilKetoconazole | 20 mg/g CreamAluminum Tube x 5 g Box of 1’s | OTC | T.O. Chemicals (1979) Ltd.Thailand | Lordla Pharma Sales | DR-XY25062 | Apr 14, 2029 | |
MeedzoleKetoconazole | 20 mg/g (2% w/w) Topical CreamAluminum Tube x 5g (Box of 1's) | OTC | Lloyd Laboratories, Inc.Philippines | Medical Supplies & Equipment DistributorTrader: Euro-Health Care Exponents, Inc. | DRP-2532-02 | Mar 15, 2029 | |
NekozolKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g | OTC | Lincoln Pharmaceuticals Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-12567-01 | Sep 2, 2027 | |
NeoconazolKetoconazole | 20 mg / g (2% w/w) Topical CreamLaminated Tube x 15 g (Box of 1's) | Rx | Zee Laboratories LimitedIndia | Eon Pharmatek Inc. | DRP-15050 | Mar 9, 2028 | |
NizochemKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube with milky white cap having a piercing point x 15 g (Box of 1’s) | Rx | S Kant Healthcare LtdIndia | Wellchem Pharmaceutical Products | DRP-10225 | Aug 12, 2031 | |
NizoralKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 3.5 g, 5 g and 10 g (Box of 1's) | HR | Interphil Laboratories, Inc.Philippines | Trader: Johnson & Johnson (Phils.), Inc. | DRHR-423 | Feb 10, 2027 | |
NizoralKetoconazole | 20 mg/g (2%) ShampooFoil Sachet x 6 mL (Box of 48's) | Rx | Interphil Laboratories, Inc.Philippines | Zuellig Pharma Corporation | DRHR-402 | Apr 18, 2031 | |
NoneKetoconazole | 2 % w/v Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Mediwin PharmaceuticalsIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-4513-01 | Jul 18, 2028 | |
NoneKetoconazole | 2 % w/v Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Mediwin PharmaceuticalsIndia | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-4513-02 | Jul 18, 2028 | |
NoneKetoconazole | 2% w/v Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Mediwin PharmaceuticalsIndia | PharmaVital Corp.Importer: Ambica International Corporation | DRP-4513-03 | Jul 18, 2028 | |
NoneKetoconazole | 20 mg/ g ShampooAluminum sachet x 6 mL Box of 48's | Rx | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DRHR-1931 | Jul 22, 2029 | |
NoneKetoconazole | 20 mg/ g ShampooHDPE Bottle x 60 mL | HR | Amherst Laboratories, Inc.Philippines | Trader: RITEMED PHILS., INC. | DRHR-1932 | Jul 22, 2029 | |
NoneKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821-02 | Jun 29, 2027 | |
NoneKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g Box of 1's | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821-03 | Jun 29, 2027 | |
NoneKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g Box of 1's | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821-05 | Jun 29, 2027 | |
NoneKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Sotac Pharmaceuticals Pvt. Ltd.India | ATC Healthcare International Corp.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3821-06 | Jun 29, 2027 | |
NoneKetoconazole | 20 mg/g (2% w/w) Topical CreamAluminum Tube x 5 g and 15 g (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2532 | Mar 15, 2029 | |
NovazolKetoconazole | 20 mg/g (2% w/w) CreamAluminum Tube x 15g (Box of 1's) | OTC | S Kant Healthcare Ltd.India | Medinova Pharmaceutical, Inc. | DRP-14803 | Jan 11, 2029 | |
PhytoralKetoconazole | 20 mg/g (2% w/w Ointment)Aluminum Tube x 15 g (Box of 1's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY29106 | Oct 20, 2031 | |
PorazoleKetoconazole | 20mg/g (2% w/w) CreamAluminum Collapsible Tube x 5 g, 10 g, 15 g, 20 g, 30 g (Box of 1's) | Rx | Kwality Pharmaceutical Ltd.India | Pors Pharma Trading | DRP-14177 | Jul 14, 2028 | |
RetaconazolKetoconazole | 20 mg / g (2% w/w) CreamAluminum Tube x 15 g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Reta DrugImporter: Aglobal Care, Inc. | DRP-11793-02 | Apr 29, 2027 | |
SaphconazoleKetoconazole | 20 mg/g (2% w/w) Cream10 g, 15 g and 20 g Aluminum Collapsible Tube (Box of 1's) | Rx | Azine Healthcare Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-13348 | Feb 2, 2028 | |
UnbrandedKetoconazole | 20 mg/ g (2% w/w) CreamAluminum Collapsible Tube with Polypropylene Cap x 3.5 g and 5 g (Box of 1's) | OTC | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY29094 | Oct 27, 2031 | |
UnbrandedKetoconazole | 20mg/g (2% w/w) Cream10g Aluminum Collapsible Tube | Rx | M.C.B. Dermatological ProductsPhilippines | — | DR-XY45422 | Jun 1, 2031 | |
ZoloralKetoconazole | 20 mg/g (2% w/w) CreamAluminum Collapsible Tube x 10 g | OTC | PT. Ikhapharmindo PutramasIndonesia | Exa Life Care Pharma Inc. | DRP-17098 | Sep 25, 2030 | |
(no brand name)Ketoconazole | 20 mg/g (2%) ShampooHDPE Bottle with PP cap x 50mL | HR | OLIC (Thailand) LimitedThailand | Zuellig Pharma CorporationTrader: Alliance Pharmaceuticals Limited | DRHR-2476 | Oct 24, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3. DOSAGE FORMS AND STRENGTHS Ketodan ® Foam, 2% contains 20 mg of ketoconazole, USP per gram, supplied in 100 g containers. Foam: 2% ketoconazole in 100 g containers (3).
Warnings/Precautions
5. WARNINGS AND PRECAUTIONS Ketodan ® Foam, 2% may result in contact sensitization, including photoallergenicity (5.1, 6.2). The contents of Ketodan ® Foam, 2% are flammable. Avoid fire, flame, or smoking during and immediately following application. (5.2).
5.1 Contact Sensitization Ketodan
5.1 Contact Sensitization Ketodan ® Foam, 2% may result in contact sensitization, including photoallergenicity [see Adverse Reactions (6.2)].
5.2 Flammable Contents
5.2 Flammable Contents The contents of Ketodan ® Foam, 2% include alcohol and propane/butane, which are flammable. Avoid fire, flame and/or smoking during and immediately following application. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C).
5.3 Systemic Effects
5.3 Systemic Effects Hepatitis has been seen with orally administered ketoconazole (1:10,000 reported incidence). Lowered testosterone and ACTH–induced corticosteroid serum levels have been seen with high doses of orally administered ketoconazole. These effects have not been seen with topical ketoconazole.
Adverse reactions
6. ADVERSE REACTIONS The most common adverse reactions observed in clinical studies (incidence >1%) were application site burning and application site reaction (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Medimetriks at 1-973-882-7512 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse reactions that appear to be related to drug use and for approximating rates.
The safety data presented in Table 1 reflect exposure to ketoconazole foam, 2% in 672 subjects, 12 years and older with seborrheic dermatitis. Subjects applied ketoconazole foam, 2% or vehicle foam twice daily for 4 weeks to affected areas on the face, scalp, and/or chest. Adverse reactions occurring in > 1% of subjects are presented in Table 1.
Table 1: Adverse Reactions Reported by > 1% Subjects in Clinical Trials Adverse Reactions Ketoconazole Foam, 2% N = 672 n (%) Vehicle Foam N = 497 n (%) Subjects with an Adverse Reaction 188 (28%) 122 (25%) Application site burning 67 (10%) 49 (10%) Application site reaction 41 (6%) 24 (5%) Application site reactions that were reported in <1% of subjects were dryness, erythema, irritation, paresthesia, pruritus, rash and warmth.
6.2 Dermal Safety Studies
6.2 Dermal Safety Studies In a photoallergenicity study, 9 of 53 subjects (17%) had reactions during the challenge period at both the irradiated and non-irradiated sites treated with ketoconazole foam, 2%. Ketodan ® Foam, 2% may cause contact sensitization.
6.3 Postmarketing Experience
6.3 Postmarketing Experience The following adverse events have been identified during postmarketing use of ketoconazole foam, 2%: Gastrointestinal disorders: Cheilitis General disorders and administration site conditions: Application site pain and application site burn Skin and subcutaneous tissue disorders: Skin burning sensation and erythema Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reactions | Ketoconazole Foam, 2% N = 672 n (%) | Vehicle Foam N = 497 n (%) |
|---|---|---|
| Subjects with an Adverse Reaction | 188 (28%) | 122 (25%) |
| Application site burning | 67 (10%) | 49 (10%) |
| Application site reaction | 41 (6%) | 24 (5%) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no available data on ketoconazole foam, 2% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. No reproductive studies in animals have been performed with ketoconazole foam, 2%. In animal reproduction studies with pregnant mice, rats and rabbits both embryotoxic and developmental effects (structural abnormalities) were observed following oral dosing of ketoconazole during organogenesis.
Assuming equivalent systemic absorption of topical and oral ketoconazole doses and a ketoconazole foam, 2% maximum recommended human dose (MRHD) of 8 grams (equivalent to 160 mg ketoconazole), embryotoxic effects were observed at 0.8 to 2.4 times the MRHD and developmental effects were observed at 4.8 times the MRHD [see Data]. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data The animal multiples of human exposure calculations are based on body surface area (BSA) comparisons of oral doses administered to animals and a ketoconazole foam, 2% maximum recommended human dose (MRHD) of 8 grams (equivalent to 2.67 mg ketoconazole/kg/day for a 60 kg individual or 98.8 mg ketoconazole/m 2 /day).
Embryofetal development studies have been conducted in mice, rats and rabbits with orally administered ketoconazole. When orally administered to mice on gestational days 6 through 18 (covering the period of organogenesis), ketoconazole was embryotoxic (25 mg/kg and higher; 0.8 times the MRHD based on BSA comparisons) with a high incidence of resorptions, increased number of stillbirths and delayed parturition.
Delays in maturation were also observed. There was no evidence of maternal toxicity or malformations at up to 50 mg/kg (1.5 times the MRHD based on BSA comparisons). No treatment related developmental effects were observed at 10 mg/kg (0.3 times the MRHD based on BSA comparisons). In the presence of maternal toxicity in rats, orally administered ketoconazole was both embryotoxic (40 mg/kg and higher; 2.4 times the MRHD based on BSA comparisons), including increased resorbed fetuses and stillbirths, and teratogenic (80 mg/kg and higher; 4.8 times the MRHD based on BSA comparisons), including syndactylia, oligodactylia, waved ribs and cleft palate.
Additionally, 100 mg/kg (6 times the MRHD based on BSA comparisons) ketoconazole orally administered on a single day during gestation (gestational days 9 through 12) was embryotoxic (increased resorptions). This same oral dose given on gestation day 12, 13, 14 or 15 induced external malformations including cleft palate, micromelia and digital anomalies (brachydactyly, ectrodactyly, syndactyly).
In pregnant rabbits orally administered ketoconazole, evidence of embryotoxicity (increased resorptions) was observed at 10 mg/kg (1.2 times the MRHD based on BSA comparisons) and higher and an increased incidence of skeletal abnormalities was observed at 40 mg/kg (4.8 times the MRHD based on BSA comparisons).
Mechanism of action
12.1 Mechanism of Action The mechanism of action of ketoconazole in the treatment of seborrheic dermatitis is not known.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The pharmacodynamics of Ketodan ® Foam, 2% has not been established.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics In a bioavailability study, 12 subjects with moderate to severe seborrheic dermatitis applied 3 g of ketoconazole foam, 2% twice daily for 4 weeks. Circulating plasma levels of ketoconazole were < 6 ng/mL for a majority of subjects (75%), with a maximum level of 11 ng/mL observed in one subject.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ketoconazole 2%, 15 g aluminum tube | ₱67.33–₱115.00Reference ₱78.00 | per tube | DPRI procurement range |
| 2% (20 mg/g) cream in 15 g aluminum collapsible tube | ₱91.50 | per tube | PhilHealth GAMOT fixed fee |
| 2% (20 mg/g) cream in 3.5 g aluminum collapsible tube | ₱118.75 | per tube | PhilHealth GAMOT fixed fee |
| 2% (20 mg/g) shampoo in 100 mL bottle | ₱433.50 | per bottle | PhilHealth GAMOT fixed fee |
| 2% (20 mg/g) shampoo in 6 mL foil sachet | ₱51.75 | per sachet | PhilHealth GAMOT fixed fee |
| 2% (20 mg/g) shampoo in 60 mL bottle | ₱242.25 | per bottle | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Ketoconazole |
| PNF listing | Cream: 2% (20 mg/ g), 3.5 g and 15 g aluminum collapsible tube |
| PNF listing | Shampoo: 2% (20 mg/ g), 6 mL foil sachet, 10 mL, 60 mL and 100 mL bottle |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Ketodan · Medimetriks Pharmaceuticals, Inc. [US FDA-approved label, version 8, December 5, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62f19bd8-926e-4e6b-9097-d81b894b95cc
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .